Shorla Oncology and Eversana announce US launch of first oral methotrexate solution

According to Shorla, the treatment has a ‘sweet’ and ‘palatable’ taste and is approved to treat adults with acute lymphoblastic leukemia as part of a combination chemotherapy maintenance regimen.

"We are delighted to introduce JYLAMVO as an alternative treatment option for patients who may have difficulty swallowing pills," said Sharon Cunningham, CEO of Shorla Oncology.

"This is our second product launch in the U.S. Market in 2023, and today's announcement is another significant advancement in our pipeline and our mission to bring new therapeutic options to patients in need."

JYLAMVO received FDA approval in November 2022 and was acquired by Shorla Oncology in October 2023.

In addition, the solution is stable at room temperature for 90 days and does not require refrigeration.

Eversana, the commercialization partner to Shorla, will provide launch support including field deployment sales and training solutions, medical information, pharmacovigilance and quality services, as well as revenue management.

"We have immediately activated our full commercialization engine, combined with in-depth knowledge of the complex methotrexate market, to help patients who have waited far too long for other treatment options that can help meet their needs," said Jim Lang, CEO of Eversana.

"Today's announcement showcases the partnership we have built with the Shorla team, and we look forward to continuing to support their growing portfolio of therapies for patients in need."

As well as JYLAMVO, Shorla Oncology has an advanced pipeline of oncology therapies to treat a number of unmet patient needs.